Join to view full profile
18000 Studebaker RdSte 800Cerritos, CA 90703
Phone+1 562-735-3226
Dr. Mazumder is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1979 - 1983
Baylor College of MedicineResidency, Internal Medicine, 1977 - 1979
Johns Hopkins University School of MedicineClass of 1977
Certifications & Licensure
CA State Medical License 2016 - 2028
NY State Medical License 1998 - 2023
DC State Medical License 1991 - 2013
MD State Medical License 1979 - 1991
TX State Medical License 1984 - 1986
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2012, 2014
Clinical Trials
- Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants with Relapsed/Refractory Cancer Indications
Roles: Principal Investigator, Contact
- A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma Start of enrollment: 2020 Sep 03
Roles: Principal Investigator, Contact
Publications & Presentations
PubMed
- Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, ope...Meletios A Dimopoulos, Fredrik Schjesvold, Chengcheng Fu, Monique A Hartley-Brown, Cesar Gomez
Lancet. 2026-07-18 - 11 citationsFilanesib plus bortezomib and dexamethasone in relapsed/refractory t(11;14) and 1q21 gain multiple myeloma.Darren Pan, Jonathan L Kaufman, Myo Htut, Manish Agrawal, Amitabha Mazumder
Cancer Medicine. 2022-01-01 - 12 citationsPatient-reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON study.Alessandra Larocca, Xavier Leleu, Cyrille Touzeau, Joan Bladé, Agne Paner
British Journal of Haematology. 2021-10-21
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
